ACTRN12623001273673尚未招募未知
An 8-week randomised double blind placebo-controlled trial assessing the effect of a prebiotic fiber versus corn starch on gut microbiome and surgical outcomes of patients with prosthetic joint infection
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Adult patients with a first-time diagnosis of PJI as per Musculoskeletal Infection Society (MSIS) criterion and scheduled to undergo two-stage revision at the Royal Adelaide Hospital
- •· Under the care of orthopaedic surgeons at the RAH
- •Willing to participate in the study.
- •Well enough to undergo two-stage revision surgery.
排除标准
- •Patients with chronic PJI
- •Patients who do not consent to the study.
- •Pregnant and Breast-feeding women
- •Patients who cannot tolerate prebiotic fibres
- •Patients who are immunosuppressed and on dietary restrictions
研究者
相似试验
已完成
不适用
A 8-week randomized, double-blind, placebo-controlled trial to improve intestinal healthDiseases of the digestive systemKCT0009026Ildong Bioscience30
尚未招募
4 期
An 8 week randomised, double-blind, placebo controlled trial investigating the role of adjunctive bioactive lipids specifically; docosahexaenoic acid (DHA) versus eicosapentaenoic acid (EPA) in Major Depressive Disorder - with a 6 week open label extension of DHA in patients aged 18-65years.ACTRN12610000710022The Melbourne Clinic90
进行中（未招募）
1 期
An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2)COVID-19 development in hospitalized patients infected with SARS-CoV-2MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862EUCTR2020-005849-16-BGKinarus AG432
进行中（未招募）
1 期
An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2)COVID-19 development in hospitalized patients infected with SARS-CoV-2MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862EUCTR2020-005849-16-DEKinarus AG432
进行中（未招募）
2 期
The role of resveratrol in the management of metabolic dysregulations in non-alcoholic fatty liver disease: a randomised placebo controlled clinical trialnon-alcoholic fatty liver diseaseMetabolic and Endocrine - Metabolic disordersDiet and Nutrition - ObesityOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12612001135808Metro-South Queensland health20